{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-005489","form_type":"8-K","ticker":"JAGX","cik":"0001585608","company_name":"Jaguar Health, Inc.","filed_at":"2023-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.715964+00:00","generated_at":"2026-06-20T11:47:00.551347+00:00","sec_items":["3.03","5.03","5.07","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Jaguar Health approves 1-for-75 reverse stock split; Phase 3 crofelemer trial to complete Q2 2023","bullets":["Reverse stock split 1-for-75 effective Jan 23, 2023; new CUSIP 47010C706.","All three stockholder proposals approved at Jan 20 special meeting.","Pivotal Phase 3 OnTarget trial of crofelemer for CTD; enrollment completion expected Q2 2023.","Proof-of-concept trial for SBS/CDD underway; potential early access programs in Europe in 2023.","No fractional shares; cash in lieu; trading continues on Nasdaq under symbol JAGX."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-005489","json":"https://secwatch.observer/filing/0001104659-23-005489.json","markdown":"https://secwatch.observer/filing/0001104659-23-005489.md","text":"https://secwatch.observer/filing/0001104659-23-005489.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923005489/0001104659-23-005489-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923005489/tm234025d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T11:47:00.551347+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f5403fb16b534391bb217b2e836b646f7f1e9c33","claim":"Jaguar Health, Inc.: Filed Seventh Amendment to Certificate of Incorporation to effect a 1-for-75 reverse stock split of common stock (effective 2023-01-23).","evidence_excerpt":"On January 20, 2023, the Company filed the Seventh Amendment with the Secretary of State of the State of Delaware, and the Reverse Stock Split will become effective in accordance with the terms of the Seventh Amendment at 12:01 am Eastern Time on January 23, 2023 (the \"Effective Time\").","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923005489/0001104659-23-005489-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-01-23"}],"fact_type":"governance_change"},{"claim_id":"1c78f8aced76a2b5c0c275da5f1e76acc41ea7d9","claim":"Jaguar Health, Inc. shareholders approved Approve amendment to Certificate of Incorporation to effect a reverse stock split at a ratio of not less than 1-for-3 and not greater than 1-for-75 at the 2023-01-20 meeting.","evidence_excerpt":"Proposal to approve an amendment to the Company’s Third Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Company’s issued and outstanding voting common stock, par value $0.0001 per share, at a ratio of not less than 1-for-3 and not greater than 1-for-75, with the exact ratio, if approved and effected at all, to be set within that range at the discretion of the Company’s board of directors and publicly announced by the Company on or before January 22, 2024 without further approval or authorization of the Company’s stockholders, was approved by the stockholders by the following vote: For Against Abstained Broker Non- Votes 51,789,833,999 8,053,911,756 237,731,178 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923005489/0001104659-23-005489-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-01-20"}],"fact_type":"shareholder_vote"},{"claim_id":"6b5e8e30f95d8c17ec2cd2baac85a5d8bd09bdc3","claim":"Jaguar Health, Inc. shareholders approved Approve one or more adjournments of the Special Meeting to solicit additional proxies if necessary at the 2023-01-20 meeting.","evidence_excerpt":"Proposal to approve one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting to approve Proposals 1 and 2, was approved by the stockholders by the following vote : For Against Abstained Broker Non- Votes 71,451,220 8,917,441 1,108,272 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923005489/0001104659-23-005489-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-01-20"}],"fact_type":"shareholder_vote"},{"claim_id":"ca87850690bd22835e558499af38aa873cdd2a0f","claim":"Jaguar Health, Inc. shareholders approved Approve issuance of common stock equal to 20% or more of outstanding common stock in one or more non-public capital raising transactions at the 2023-01-20 meeting.","evidence_excerpt":"Proposal to approve, pursuant to Nasdaq Marketplace Rule 5635(d), the issuance of Company’s common stock equal to 20% or more the Common Stock outstanding before the issuance in one or more non-public capital raising transaction, was approved by the stockholders by the following vote: For Against Abstained Broker Non- Votes 51,998,893 8,409,585 958,116 20,110,339","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923005489/0001104659-23-005489-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-01-20"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}